We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
NICE has recommended Strensiq in a wider group of patients with the ultra-rare disease paediatric-onset hypophosphatasia, after Alexion agreed a price cut.